Key result
Losartan plus propranolol reduces aortic root dilatation and controls heart failure in a Marfan neonate.
Why the study?
Treatment for neonatal Marfan syndrome has not been well studied due to the rarity and severity of the condition.
Does the combination of losartan and propranolol reduce aortic root dilatation in a patient with neonatal Marfan syndrome?
Case Report (n=1)
Does the combination of losartan and propranolol reduce aortic root dilatation in a patient with neonatal Marfan syndrome?
Combination therapy with losartan and propranolol may slow aortic root dilatation and help control heart failure in neonatal Marfan syndrome.
May warrant individualized use in refractory neonatal Marfan cases; hypothesis-generating and requires prospective confirmation before broader adoption.
Neonatal Marfan syndrome, in contrast to classical Marfan syndrome, is characterized by rapidly progressive multi-valvular cardiac disease and death from congestive heart failure, typically within the first year of life. Due to the rarity of this condition, treatment for neonatal Marfan syndrome has not been well studied. In this report, a combination of losartan and propranolol reduced the aortic root dilatation rate after three months of losartan therapy. Genetic analysis in this patient revealed a mutation in exon 25 of the FBN1 gene, which typically results in a shorter life expectancy. However, the patient's heart failure was controlled by losartan, propranolol and other anti-congestive medications, which may have prolonged his survival.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) conducted a case report in Neonatal Marfan syndrome (n=1). Losartan in combination with propranolol was evaluated on Aortic root dilatation rate. A combination of losartan and propranolol reduced the aortic root dilatation rate and controlled heart failure in a neonate with Marfan syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: